Exhibit 99.2
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Cortexyme, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule13d-1(d) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.
This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
Date: May 20, 2019
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||
By | /s/ Yoshihiro Nakagawa | |||
Name: | Yoshihiro Nakagawa | |||
Title: | Corporate Officer, Global General Counsel |
TAKEDA PHARMACEUTICALS INTERNATIONAL AG | ||||
By | /s/ Andrea Ferrari | |||
Name: | Andrea Ferrari | |||
Title: | Director and Secretary VP, Regional General Counsel Europe and Canada |
TAKEDA PHARMACEUTICALS U.S.A., INC. | ||||
By | /s/ Paul Sundberg | |||
Name: | Paul Sundberg | |||
Title: | Assistant Secretary |
TAKEDA VENTURES, INC. | ||||
By | /s/ Michael Martin | |||
Name: | Michael Martin | |||
Title: | President |